Nonetheless, pooled estimates show that the VE against symptomatic disease wanes at a rate comparable to that of the primary cycle, with VE decreasing from 60.4% (95% CI, 55.5%-65.4%) at 1 month after the administration of the booster dose to 13.3% (95% CI, 7.2%-19.4%) at 9 months.